Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Veerle M. Coupé"'
Autor:
Carmen Rubio-Alarcon, Steven L. Ketelaars, Ingrid A. Franken, Sietske C. van Nassau, Dave E. van der Kruijssen, Suzanna J. Schraa, Theodora C. Linders, Pien Delis-van Diemen, Maartje Alkemade, Anne Bolijn, Marianne Tijssen, Margriet Lemmens, Miranda van Dongen, Mirthe Lanfermeijer, Annegien Broeks, Lana Meiqari, Linda J. Bosch, Victor E. Velculescu, Amy Greer, Samuel V. Angiuoli, Andrew Georgiadis, David Riley, James R. White, Christopher Greco, Liam Cox, Daan van den Broek, Cornelis J. Punt, Veerle M. Coupé, Miriam Koopman, Jeanine Roodhart, Gerrit A. Meijer, Mark Sausen, Geraldine R. Vink, Remond J. Fijneman
Publikováno v:
Cancer Research. 83:3358-3358
Introduction: Surgery followed by adjuvant chemotherapy (ACT) is standard of care in stage III colon cancer. However, 50% of the patients would be cured by surgery alone and are being overtreated, while 30-35% will experience a recurrence despite adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::621b6e878dc8e83850585bd73d2b181c
https://doi.org/10.1158/1538-7445.am2023-3358
https://doi.org/10.1158/1538-7445.am2023-3358
Autor:
Miranda L van Hooff, Johanna M van Dongen, Veerle M Coupé, Maarten Spruit, Raymond W J G Ostelo, Marinus de Kleuver
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203518 (2018)
INTRODUCTION:Chronic Low Back Pain (CLBP) is a heterogeneous condition with lack of diagnostic clarity. Therapeutic interventions show small effects. To improve outcomes by targeting interventions it is recommended to develop a triage system to surgi
Externí odkaz:
https://doaj.org/article/3ab744ad982042f5849dc225d652f5c8
Autor:
Carmen Rubio Alarcon, Dave E. van der Kruijssen, Suzanna J. Schraa, Sietske C. Nassau, Leticia G. León, Lana Meiqari, Linda J. Bosch, John K. Simmons, Mark Sausen, Amy Greer, Samuel V. Angiuoli, Jeanine M. Roodhart, Victor E. Velculescu, Daan van den Broek, Cornelis J. Punt, Veerle M. Coupé, Miriam Koopman, Gerrit A. Meijer, Geraldine R. Vink, Remond J. Fijneman
Publikováno v:
Cancer Research. 82:536-536
Introduction: Stage III colon cancer patients are offered surgery followed by adjuvant chemotherapy (ACT) according to Dutch clinical guidelines. However, only 15-20% of the patients benefit from ACT: 50% would be cured by surgery alone and are thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d526fe635ebfb2f25fde1cc47775a7b8
https://doi.org/10.1158/1538-7445.am2022-536
https://doi.org/10.1158/1538-7445.am2022-536
Autor:
van Hooff, Miranda L.1,2 m.vanhooff@maartenskliniek.nl, van Dongen, Johanna M.3, Coupé, Veerle M.4, Spruit, Maarten5, Ostelo, Raymond W. J. G.3,4, de Kleuver, Marinus2
Publikováno v:
PLoS ONE. 9/19/2018, Vol. 13 Issue 9, p1-18. 18p.
Autor:
Remond J.A. Fijneman, Helma van Grevenstein, Victor E. Velculescu, Linda J.W. Bosch, Karlijn L. van Rooijen, Miriam Koopman, Veerle M.H. Coupé, John K. Simmons, Daan van den Broek, Geraldine R. Vink, Amy Greer, Suzanna J. Schraa, Miranda M.W. van Dongen, Sjoerd G. Elias, Jillian Phallen, Samuel V. Angiuoli, Helena M. Verkooijen, Carmen Rubio Alarcón, Dave E. W. van der Kruijssen, Gerrit A. Meijer
Publikováno v:
Cancer Research. 81:CT251-CT251
Background Accurate detection of patients with minimal residual disease (MRD) after resection of localized colon cancer remains an unmet clinical need as these patients might benefit from adjuvant chemotherapy (ACT). For stage II colon cancer, ACT is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41e88a9f2765a75544ca1b467df64b95
https://doi.org/10.1158/1538-7445.am2021-ct251
https://doi.org/10.1158/1538-7445.am2021-ct251
Autor:
Remond J.A. Fijneman, Linda J.W. Bosch, Miriam Koopman, Carmen Rubio Alarcón, John K. Simmons, Dave E. W. van der Kruijssen, Gerrit A. Meijer, Veerle M.H. Coupé, Lana Meiqari, Victor E. Velculescu, Geraldine R. Vink, Cornelis J. A. Punt, Daan van den Broek
Publikováno v:
Cancer Research. 80:3096-3096
Introduction: Stage III colon cancer patients undergo surgery followed by adjuvant chemotherapy (ACT) according to clinical guidelines. However, 50% would be cured by surgery alone and are being overtreated, while 30-35% will relapse despite adjuvant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b06a9064399ed69bd11c55bf3cf3196
https://doi.org/10.1158/1538-7445.am2020-3096
https://doi.org/10.1158/1538-7445.am2020-3096
Autor:
Karlijn L. van Rooijen, Geraldine R. Vink, Theodora C. Linders, Daan van den Broek, Remond J.A. Fijneman, Boris van Doorn, Miriam Koopman, Kalpana L. Ramkisoensing, Daan C L Vessies, Gerrit A. Meijer, Mirthe Lanfermeijer, Flore E. Grijseels, Veerle M.H. Coupé, Marjolein J E Greuter
Publikováno v:
Cancer Research. 79:2276-2276
Purpose The field of circulating cell free DNA (cfDNA) testing is quickly developing. Multiple platforms to detect hotspot mutations in ctDNA are available, including Bio-Rad droplet digital PCR (ddPCR), BioCartis Idylla, Roche COBAS z480 and Sysmex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5876c6dacff0fe3639df859c59747ea8
https://doi.org/10.1158/1538-7445.am2019-2276
https://doi.org/10.1158/1538-7445.am2019-2276